The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC).
The European Centre for Disease Prevention and Control (ECDC) has published a report today highlighting the threat of increasing antimicrobial resistance (AMR) in Neisseria gonorrhoeae.
The Emerging and Vector-borne Diseases (EVD) team of ECDC communicates, consults and cooperates with EVD-Net on surveillance, response, prevention, control and preparedness aspects of EVDs and vectors, with particular focus on country needs and country support possibilities.
Between 2018 and 2020, nearly 20 000 surgical site infections (SSIs) were reported from a total of over 1.2 million surgical procedures in 13 EU/EEA countries participating in ECDC-coordinated SSI surveillance. Over 2 500 hospitals are part of this surveillance network.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
The laboratories participating in the QA21 EQA scheme for antimicrobial susceptibility testing of N. gonorrhoeae showed good levels of competency and capability in recovering and testing strains of unknown phenotype.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.